Standard BioTools Q1 2024 GAAP EPS $(0.27) Misses $(0.12) Estimate, Sales $45.540M Miss $46.006M Estimate
Standard BioTools Q1 2024 GAAP EPS $(0.27) Misses $(0.12) Estimate, Sales $45.540M Miss $46.006M Estimate
Standard BioTools 2024年第一季度GAAP每股收益（0.27）未达到预期（0.12）美元，销售额为4554万美元，低于4,6006万美元的预期
Standard BioTools (NASDAQ:LAB) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.12) by 125 percent. This is a 28.57 percent decrease over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $45.540 million which missed the analyst consensus estimate of $46.006 million by 1.01 percent. This is a 81.30 percent increase over sales of $25.119 million the same period last year.
标准生物工具（纳斯达克股票代码：LAB）公布的季度亏损为每股0.27美元，比分析师普遍预期的0.12美元（0.12美元）低125％。这比去年同期每股亏损0.21美元（0.21美元）下降了28.57％。该公司公布的季度销售额为4,554万美元，比分析师普遍预期的4,6006万美元低1.01％。这比去年同期的251.19亿美元的销售额增长了81.30％。